Sigilon Therapeutics, Inc. SGTX
We take great care to ensure that the data presented and summarized in this overview for Sigilon Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SGTX
Top Purchases
Top Sells
About SGTX
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SGTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2023
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
797,720
-100.0%
|
$11,168,080
$14.92 P/Share
|
|
Aug 11
2023
|
Lilly & CO Eli > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,718,493
+99.99%
|
$24,058,902
$14.92 P/Share
|
|
Aug 11
2023
|
Josias Pontes CHIEF FINANCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,504
-100.0%
|
-
|
|
Aug 11
2023
|
Coelho Rogerio Vivaldi PRESIDENT AND CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,169
-100.0%
|
-
|
|
Aug 11
2023
|
Qing Sarah Yuan CTOO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,884
-100.0%
|
-
|
|
Aug 11
2023
|
Matthew Paul Kowalsky CHIEF OF STAFF AND CLO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,925
-100.0%
|
-
|
|
Aug 11
2023
|
John Cox |
SELL
Sale (or disposition) back to the issuer
|
Direct |
341
-100.0%
|
-
|
|
Jul 27
2023
|
Qing Sarah Yuan CTOO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,884
+50.0%
|
$54,796
$19.24 P/Share
|
|
Jul 21
2023
|
Coelho Rogerio Vivaldi PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,528
+31.6%
|
$105,032
$19.24 P/Share
|
|
Jul 21
2023
|
Josias Pontes CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,444
+30.74%
|
$27,436
$19.24 P/Share
|
|
Nov 04
2021
|
Coelho Rogerio Vivaldi PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+40.5%
|
-
|
|
Sep 30
2021
|
Josias Pontes CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
11,500
+46.3%
|
-
|
|
Jul 01
2021
|
Robert R Ruffolo |
SELL
Open market or private sale
|
Direct |
6,750
-100.0%
|
$67,500
$10.36 P/Share
|
|
Jul 01
2021
|
Robert R Ruffolo |
BUY
Exercise of conversion of derivative security
|
Direct |
6,750
+50.0%
|
$0
$0.57 P/Share
|
|
Jun 02
2021
|
Daniel Griffith Anderson |
SELL
Open market or private sale
|
Direct |
200,000
-9.0%
|
$2,000,000
$10.0 P/Share
|
|
Dec 08
2020
|
Coelho Rogerio Vivaldi PRESIDENT AND CEO |
BUY
Conversion of derivative security
|
Direct |
22,222
+50.0%
|
-
|
|
Dec 08
2020
|
John Cox |
BUY
Conversion of derivative security
|
Indirect |
4,444
+50.0%
|
-
|
|
Dec 08
2020
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
10,370,369
+50.0%
|
-
|
|
Dec 08
2020
|
Lilly & CO Eli > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
300,000
+9.85%
|
$5,400,000
$18.0 P/Share
|
|
Dec 08
2020
|
Lilly & CO Eli > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,444,443
+50.0%
|
-
|